Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
Location: Switzerland
Total raised: $3.38M
Investors 2
| Date | Name | Website |
| 25.06.2025 | Venture Ki... | venturekic... |
| 06.09.2025 | CARB-X | carb-x.org |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.02.2026 | - | $187.94K | Venture Ki... |
| 17.11.2025 | Grant | $187.94K | - |
| 22.08.2025 | - | $3M | CARB-X |
Mentions in press and media 6
| Date | Title | Description |
| 16.06.2026 | >>venture>> awards ceremony shaped by AI | Yesterday, the awards ceremony for this year’s >>venture>> Awards took place at the Swiss Tech Convention Centre at EPFL in front of around 300 guests. A total of eight prizes were awarded. Six category winners including the Gr... |
| 12.05.2026 | >>venture>> 2026 names 18 finalists and debuts Spotlight Award | The >>venture>> competition is one of the oldest startup competitions in Switzerland. Companies compete in six verticals for the category winner award and the Grand Prize worth CHF 150,000. Vertical winners receive CHF 50,000 a... |
| 23.02.2026 | Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine | Urinary tract infections are among the most common bacterial diseases globally, and most cases are caused by E. coli. These infections can lead to serious complications, including sepsis, and cause more than 80,000 deaths each year in the ... |
| 17.11.2025 | InnoBooster supports six early-stage startups with CHF 900’000 | InnoBooster is an initiative of the Gebert Rüf Stiftung (GRS) designed to support university students that have already entered the second stage of the Venture Kick program with up to CHF 150,000 for a maximum of 1.5 years. This funding al... |
| 12.09.2025 | Newcomers in the spotlight | The ETH Pioneer Fellowship Programme has been in existence for 15 years, empowering entrepreneurs at the university to turn research results into successful start-ups. For ten years, the programme has been staging the 3Pi Pitch Competition... |
| 22.08.2025 | Baxiva secures $3 million to advance antibacterial vaccines | Escherichia coli (E. coli) is the leading cause of urinary tract infections, a frequent cause of neonatal sepsis, and is among the leading causes of antimicrobial resistance-associated deaths globally. One approach to tackle this is with m... |